A rare case of malignant hyperthermia in the Indian subcontinent

Gopalakrishnan, Chittur Viswanathan; Suparna, B.; Arun, Varatharajan Santhakumari

doi:10.1111/j.1365-2044.2010.06515.x

Cited by 8 publications

(8 citation statements)

References 4 publications

(4 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In conclusion, the case reported by Gopalakrishnan et al [1] illustrates that MH can occur in any part of India, whereas evidence from UK families of Indian subcontinent descent suggests that the prevalence of MH susceptibility in Indian populations is much higher than previously assumed. We would wish to encourage the anaesthetic community in the Indian subcontinent to work towards the setting up of MH diagnostic centres and the wider availability of dantrolene.…”

Section: Malignant Hyperthermia In Indiamentioning

confidence: 60%

“…The latest report, from Gopalakrishnan et al [1], may not, therefore, be the first case of MH in India, but as it involved a 9-year-old boy from Kerala in Southern India, it could be of significance to the genetic epidemiology of predisposition to MH in the subcontinent. Indeed, some anaesthetists from southern India and Sri Lanka have told us that MH does not exist in their populations because of their genetic isolation.…”

Section: Malignant Hyperthermia In Indiamentioning

confidence: 98%

“…Another important consideration arising from the report by Gopalakrishnan et al [1] is the availability of dantrolene in India. Dantrolene is not marketed in India, presumably through lack of demand from an anaesthetic community that believed MH was so rare in its patient population that the cost could not be justified.…”

Section: Malignant Hyperthermia In Indiamentioning

confidence: 99%

See 2 more Smart Citations

Malignant hyperthermia in India

Gupta¹,

Hopkins²

2010

Anaesthesia

View full text Add to dashboard Cite

Section: Malignant Hyperthermia In Indiamentioning

confidence: 60%

Section: Malignant Hyperthermia In Indiamentioning

confidence: 98%

See 1 more Smart Citation

Malignant hyperthermia in India

Gupta¹,

Hopkins²

2010

Anaesthesia

View full text Add to dashboard Cite

“…We are reporting this case of possible malignant hyperthermia probably the seventh reported case in India and second from Kerala in the last decade (Saxena and Dua, 2007;Punj et al, 2001;Gopalakrishnan et al, 2010;Jain, 2010;Ramakant and Singh, 2012;Sharma et al, 2012). This was the first ever case of MH in our institution in 25 years This emphasises the need to ensure availability of Dantrolene and MH kits, diagnostic centres with appropriate lab controls and above all high index of suspicion and heightened awareness among the anaesthesiologists of this potential albeit rare risk of MH in Indian population.…”

mentioning

confidence: 94%

“…We are reporting this case of possible malignant hyperthermia probably the seventh reported [1][2][3][4][5][6] case in India and second from Kerala in the last decade. This was the first ever case of MH in our institution in 25 years.…”

Section: Introductionmentioning

confidence: 99%

Malignant hyperthermia in India: Time for awakening, useful facts on Dantrolene

Pillai

Koshy

Balakrishnan

et al. 2015

Egyptian Journal of Anaesthesia

View full text Add to dashboard Cite

A 33 year old lady with no obvious reason to suspect susceptibility to malignant hyperpyrexia (MH) succumbed to this unexpected complication in spite of attempts to save her life with aggressive supportive measures. We are reporting this case of possible malignant hyperthermia probably the seventh reported case in India and second from Kerala in the last decade (Saxena and Dua, 2007;Punj et al., 2001;Gopalakrishnan et al., 2010;Jain, 2010;Ramakant and Singh, 2012;Sharma et al., 2012). This was the first ever case of MH in our institution in 25 years This emphasises the need to ensure availability of Dantrolene and MH kits, diagnostic centres with appropriate lab controls and above all high index of suspicion and heightened awareness among the anaesthesiologists of this potential albeit rare risk of MH in Indian population.

show abstract

Malignant hyperthermia in maxillofacial surgery: Literature review supported by case presentation

Aires

Souza

Amorim

et al. 2022

Special Care in Dentistry

View full text Add to dashboard Cite

Objective Malignant hyperthermia (MH) is characterized by a state of hypermetabolism after exposure to halogenated inhalational anesthetics or succinylcholine. The aims of this study were to carry out an updated review on the subject and report an illustrative case of MH in urgent maxillofacial surgery. Material and Methods A search of the PubMed/MEDLINE database using the keyword “malignant hyperthermia” was performed including articles published over the last 11 years in English, Spanish or Portuguese. Exclusion criteria were similar presentations but not associated with MH and cases not related to the use of anesthetic drugs as a trigger of the condition. Case Report A 45‐year‐old man (75 kg, ASA status IE) with a negative family history for neuromuscular diseases, victim of a car accident with a facial fracture, underwent surgery under balanced general anesthesia and developed signs of MH 4 h after anesthesia induction. In our patient, the causative agent was sevoflurane and the diagnosis of MH was confirmed, subsequently, by muscle biopsy. Results/Discussion Overall, 44 cases of MH were found. According to the recent literature, MH shows a male predilection (3:1) and the mean age of patients is 32.2 ± 22.2 years. The most frequently cited causative agents were sevoflurane (30.5%), isoflurane (22.2%), and sevoflurane + succinylcholine (13.8%). The most common clinical indicators included hypercarbia (88.8%), hyperthermia (86.1%), and tachycardia (63.8%). Dantrolene was administered in 24 cases. The outcome was favorable in 31 cases (86.1%). The in vitro muscle contracture test (IVCT) was performed in only 15 patients and all of them tested positive. In our patient, the causative agent was sevoflurane and the diagnosis of MH was confirmed by muscle biopsy. Conclusion The mortality from MH is still high and an early clinical diagnosis and specific treatment with dantrolene are necessary for a favorable outcome. A complete understanding will allow better management of patients with MH. At present, the best management is to identify susceptible patients and to avoid triggering agents, combined with vigilant monitoring.

show abstract

A rare case of malignant hyperthermia in the Indian subcontinent

Cited by 8 publications

References 4 publications

Malignant hyperthermia in India

Malignant hyperthermia in India

Malignant hyperthermia in India: Time for awakening, useful facts on Dantrolene

Malignant hyperthermia in maxillofacial surgery: Literature review supported by case presentation

Contact Info

Product

Resources

About